Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 12/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 11/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2435289 | 0.91 | MTNR1A (0.38) | MTNR1BMTNR1ARAB9A | |
| SCHEMBL2495444 | 0.81 | MTNR1A (0.37) | MTNR1BMTNR1ARAB9A | |
| SCHEMBL2440414 | 0.79 | CA14 (0.46) | MTNR1BMTNR1ARAB9A | |
| SCHEMBL2434386 | 0.76 | ALDH1A1 (0.54) | MTNR1BMTNR1AL3MBTL1USP2ALOX15 | |
| SCHEMBL14354369 | 0.76 | SYK (0.43) | MTNR1BMTNR1AL3MBTL1USP2ALOX15 | |
| SCHEMBL2436071 | 0.75 | L3MBTL1 (0.50) | MTNR1BMTNR1AL3MBTL1USP2ALOX15 | |
| SCHEMBL2432981 | 0.74 | F10 (0.55) | — | |
| SCHEMBL2435297 | 0.72 | ALDH1A1 (0.36) | MTNR1BMTNR1A | |
| SCHEMBL2434816 | 0.71 | RXRA (0.43) | L3MBTL1USP2HSD17B10 | |
| SCHEMBL2434310 | 0.71 | ACHE (0.44) | MTNR1BMTNR1AL3MBTL1USP2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542529-B1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | LLC PHARMADIALL (RU) | 2019-09-04 | — | — | EP | disclosed |
| US-9708265-B2 | Urethanes, ureas, amidines and related inhibitors of factor Xa | PHARMADIALL LIMITED LIABILITY COMPANY (RU) | 2017-07-18 | — | — | US | disclosed |
| EP-2542529-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | Tovbin, Dmitry Gennadievich (RU) | 2013-01-09 | — | — | EP | disclosed |
| US-20130005778-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | PHARMADIALL LIMITED LIABILITY COMPANY (RU) | 2013-01-03 | — | — | US | disclosed |
| WO-2011108963-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | TOVBIN DMITRY GENNADIEVICH (RU) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005778-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | PLAUR, PLAU, UTS2R | MTNR1B 4530/4885MTNR1A 4418/4885L3MBTL1 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.